Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 17, 04 December 2023
Open
Access | Article
Application of sunitinib in cancer treatment and analysis of its synthetic route
* Author to whom correspondence should be addressed.
Abstract
Sunitinib, also known as the free base of sunitinib malate, is an innovative oral agent used in the treatment of tumors. It functions by inhibiting various members of the receptor tyrosine kinase (RTK) family, which possess a split kinase structural domain. These members include vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptors (PDGFR) α and β, stem cell factor receptors, FMS-like tyrosine kinase 3, colony-stimulating factor 1 receptor, and BCR/ABL fusion genes. This paper briefly introduces the research background, pharmacological activity and toxicity of sunitinib, sorting out the incidence and pathogenesis of the diseases it is targeted to treat, and its regulatory mechanism in treating the diseases, etc., summarising several synthetic routes of sunitinib researched by the previous researchers, and at the same time analysing and evaluating the synthetic routes and suggesting the synthetic routes, summing up and proposing the outlook of its subsequent research contents and directions, providing references and help to the research on sunitinib afterward.
Keywords
Sunitinib, Gastrointestinal Mesenchymal Tumour, Renal Cell Carcinoma, Synthetic Route
References
1. Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E and Antón-Aparicio L 2011 Mol. Cancer Ther. 10 2215–2223
2. Ayala-Aguilera C C, Valero T, Lorente-Macías Á, Baillache D J, Croke S and Unciti-Broceta A 2022 J. Med. Chem. 65 1047–1131
3. Kelly C M, Gutierrez Sainz L and Chi P 2021 J. Hematol. Oncol. 14 2
4. Yonkus J A, Alva-Ruiz R and Grotz T E 2021 Curr. Treat. Options Oncol. 22 37
5. Wang Q, Gao S, Shou Y, Jia Y, Wei Z, Liu Y, Shi J, Miao D, Miao Q, Zhao C, Liu C, Yang H, Xu T and Zhang X 2023 Int. J. Biol. Sci. 19 1266–1283
6. Jin J, Xie Y, Zhang J-S, Wang J-Q, Dai S-J, He W, Li S-Y, Ashby C R, Chen Z-S and He Q 2023 Drug Resist. Updat. 67 100929
7. Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M and Mafakher L 2022 G. Ital. Nefrol. 39 2022-vol3
8. Dahle D O, Skauby M, Langberg C W, Brabrand K, Wessel N and Midtvedt K 2022 Transplantation 106 e52–e63
9. Peng Y, Dong S, Song Y, Hou D, Wang L, Li B and Wang H 2021 Cancer Med. 10 6917–6930
10. Chen M, Suzuki A, Thakkar S, Yu K, Hu C and Tong W 2016 Drug Discov. Today 21 648–653
11. Weise A M, Liu C Y and Shields A F 2009 Ann. Pharmacother. 43 761–766
12. Chen Y 2011 Synthetic Studies on Sunitinib Which Is the Antitumour Drug (Hangzhou: Zhejiang University)
13. Chen Y, Zhou X and Bai Y 2010 Chin. J. Med. Chem. 20 99–101
14. Liu B, Lin R, Liao J, Li Z and Chen K 2007 Chin. J. Pharm. 8 539–542
15. Manley J M, Kalman M J, Conway B G, Ball C C, Havens J L and Vaidyanathan R 2003 J. Org. Chem. 68 6447–6450
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-197-1
- ISBN (Online)
- 978-1-83558-198-8
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/17/20240625
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited